- ICH GCP
- US Clinical Trials Registry
- Researchers
- Canada
- Carcinoma, Endometrioid
Medical specialists from Canada tagged as investigators in clinical trials studying Carcinoma, Endometrioid
Total 12 results
-
Helen J. MackaySeen in:
- Ontario, Toronto, Odette Cancer Centre- Sunnybrook Health Sciences Centre
Trials:- NCT03660826 (Principal Investigator)
-
Jason S. YuSeen in:
- Ontario, Barrie, Royal Victoria Regional Health Centre
Trials:- NCT03914612 (Principal Investigator)
Conditions:- Endometrial Clear Cell Adenocarcinoma;
- Endometrial Dedifferentiated Carcinoma;
- Endometrial Endometrioid Adenocarcinoma;
- Endometrial Mixed Cell Adenocarcinoma;
- Endometrial Serous Adenocarcinoma;
- Endometrial Undifferentiated Carcinoma;
- Recurrent Endometrial Adenocarcinoma;
- Recurrent Endometrial Carcinoma;
- Recurrent Endometrial Clear Cell Adenocarcinoma;
- Recurrent Endometrial Dedifferentiated Carcinoma;
- Recurrent Endometrial Endometrioid Adenocarcinoma;
- Recurrent Endometrial Mixed Cell Adenocarcinoma;
- Recurrent Endometrial Serous Adenocarcinoma;
- Recurrent Endometrial Undifferentiated Carcinoma;
- Stage III Uterine Corpus Cancer AJCC v8;
- Stage IV Uterine Corpus Cancer AJCC v8
-
Jennifer BROWN BRODERICKSeen in:
- Saskatchewan, Saskatoon, Saskatoon Cancer Centre
- Saskatoon, Saskatoon Cancer Centre.(CASS)
Trials:- NCT03914612 (Principal Investigator)
- NCT03386734 (Principal Investigator)
Conditions:- Endometrial Clear Cell Adenocarcinoma;
- Endometrial Dedifferentiated Carcinoma;
- Endometrial Endometrioid Adenocarcinoma;
- Endometrial Mixed Cell Adenocarcinoma;
- Endometrial Serous Adenocarcinoma;
- Endometrial Undifferentiated Carcinoma;
- Recurrent Endometrial Adenocarcinoma;
- Recurrent Endometrial Carcinoma;
- Recurrent Endometrial Clear Cell Adenocarcinoma;
- Recurrent Endometrial Dedifferentiated Carcinoma;
- Recurrent Endometrial Endometrioid Adenocarcinoma;
- Recurrent Endometrial Mixed Cell Adenocarcinoma;
- Recurrent Endometrial Serous Adenocarcinoma;
- Recurrent Endometrial Undifferentiated Carcinoma;
- Stage III Uterine Corpus Cancer AJCC v8;
- Stage IV Uterine Corpus Cancer AJCC v8;
- Cervical Cancer
-
Josee-Lyne EthierSeen in:
- Ontario, Kingston, Kingston Health Sciences Centre
Trials:- NCT03914612 (Principal Investigator)
Conditions:- Endometrial Clear Cell Adenocarcinoma;
- Endometrial Dedifferentiated Carcinoma;
- Endometrial Endometrioid Adenocarcinoma;
- Endometrial Mixed Cell Adenocarcinoma;
- Endometrial Serous Adenocarcinoma;
- Endometrial Undifferentiated Carcinoma;
- Recurrent Endometrial Adenocarcinoma;
- Recurrent Endometrial Carcinoma;
- Recurrent Endometrial Clear Cell Adenocarcinoma;
- Recurrent Endometrial Dedifferentiated Carcinoma;
- Recurrent Endometrial Endometrioid Adenocarcinoma;
- Recurrent Endometrial Mixed Cell Adenocarcinoma;
- Recurrent Endometrial Serous Adenocarcinoma;
- Recurrent Endometrial Undifferentiated Carcinoma;
- Stage III Uterine Corpus Cancer AJCC v8;
- Stage IV Uterine Corpus Cancer AJCC v8
-
Julie-Ann R. FrancisSeen in:
- Ontario, Oshawa, Lakeridge Health Oshawa
Trials:- NCT03914612 (Principal Investigator)
Conditions:- Endometrial Clear Cell Adenocarcinoma;
- Endometrial Dedifferentiated Carcinoma;
- Endometrial Endometrioid Adenocarcinoma;
- Endometrial Mixed Cell Adenocarcinoma;
- Endometrial Serous Adenocarcinoma;
- Endometrial Undifferentiated Carcinoma;
- Recurrent Endometrial Adenocarcinoma;
- Recurrent Endometrial Carcinoma;
- Recurrent Endometrial Clear Cell Adenocarcinoma;
- Recurrent Endometrial Dedifferentiated Carcinoma;
- Recurrent Endometrial Endometrioid Adenocarcinoma;
- Recurrent Endometrial Mixed Cell Adenocarcinoma;
- Recurrent Endometrial Serous Adenocarcinoma;
- Recurrent Endometrial Undifferentiated Carcinoma;
- Stage III Uterine Corpus Cancer AJCC v8;
- Stage IV Uterine Corpus Cancer AJCC v8
-
Lacey D. PitreSeen in:
- Ontario, Sudbury, Health Sciences North
Trials:- NCT03914612 (Principal Investigator)
Conditions:- Endometrial Clear Cell Adenocarcinoma;
- Endometrial Dedifferentiated Carcinoma;
- Endometrial Endometrioid Adenocarcinoma;
- Endometrial Mixed Cell Adenocarcinoma;
- Endometrial Serous Adenocarcinoma;
- Endometrial Undifferentiated Carcinoma;
- Recurrent Endometrial Adenocarcinoma;
- Recurrent Endometrial Carcinoma;
- Recurrent Endometrial Clear Cell Adenocarcinoma;
- Recurrent Endometrial Dedifferentiated Carcinoma;
- Recurrent Endometrial Endometrioid Adenocarcinoma;
- Recurrent Endometrial Mixed Cell Adenocarcinoma;
- Recurrent Endometrial Serous Adenocarcinoma;
- Recurrent Endometrial Undifferentiated Carcinoma;
- Stage III Uterine Corpus Cancer AJCC v8;
- Stage IV Uterine Corpus Cancer AJCC v8
-
Maged M. SalemSeen in:
- New Brunswick, Moncton, The Moncton Hospital
Trials:- NCT03914612 (Principal Investigator)
Conditions:- Endometrial Clear Cell Adenocarcinoma;
- Endometrial Dedifferentiated Carcinoma;
- Endometrial Endometrioid Adenocarcinoma;
- Endometrial Mixed Cell Adenocarcinoma;
- Endometrial Serous Adenocarcinoma;
- Endometrial Undifferentiated Carcinoma;
- Recurrent Endometrial Adenocarcinoma;
- Recurrent Endometrial Carcinoma;
- Recurrent Endometrial Clear Cell Adenocarcinoma;
- Recurrent Endometrial Dedifferentiated Carcinoma;
- Recurrent Endometrial Endometrioid Adenocarcinoma;
- Recurrent Endometrial Mixed Cell Adenocarcinoma;
- Recurrent Endometrial Serous Adenocarcinoma;
- Recurrent Endometrial Undifferentiated Carcinoma;
- Stage III Uterine Corpus Cancer AJCC v8;
- Stage IV Uterine Corpus Cancer AJCC v8
-
Maryam Al HaykiSeen in:
- Saskatchewan, Regina, Allan Blair Cancer Centre
Trials:- NCT03914612 (Principal Investigator)
Conditions:- Endometrial Clear Cell Adenocarcinoma;
- Endometrial Dedifferentiated Carcinoma;
- Endometrial Endometrioid Adenocarcinoma;
- Endometrial Mixed Cell Adenocarcinoma;
- Endometrial Serous Adenocarcinoma;
- Endometrial Undifferentiated Carcinoma;
- Recurrent Endometrial Adenocarcinoma;
- Recurrent Endometrial Carcinoma;
- Recurrent Endometrial Clear Cell Adenocarcinoma;
- Recurrent Endometrial Dedifferentiated Carcinoma;
- Recurrent Endometrial Endometrioid Adenocarcinoma;
- Recurrent Endometrial Mixed Cell Adenocarcinoma;
- Recurrent Endometrial Serous Adenocarcinoma;
- Recurrent Endometrial Undifferentiated Carcinoma;
- Stage III Uterine Corpus Cancer AJCC v8;
- Stage IV Uterine Corpus Cancer AJCC v8
-
Melanie Arbour-LevertSeen in:
- Quebec, Laval, Hopital de la Cite-de-la-Sante
Trials:- NCT03914612 (Principal Investigator)
Conditions:- Endometrial Clear Cell Adenocarcinoma;
- Endometrial Dedifferentiated Carcinoma;
- Endometrial Endometrioid Adenocarcinoma;
- Endometrial Mixed Cell Adenocarcinoma;
- Endometrial Serous Adenocarcinoma;
- Endometrial Undifferentiated Carcinoma;
- Recurrent Endometrial Adenocarcinoma;
- Recurrent Endometrial Carcinoma;
- Recurrent Endometrial Clear Cell Adenocarcinoma;
- Recurrent Endometrial Dedifferentiated Carcinoma;
- Recurrent Endometrial Endometrioid Adenocarcinoma;
- Recurrent Endometrial Mixed Cell Adenocarcinoma;
- Recurrent Endometrial Serous Adenocarcinoma;
- Recurrent Endometrial Undifferentiated Carcinoma;
- Stage III Uterine Corpus Cancer AJCC v8;
- Stage IV Uterine Corpus Cancer AJCC v8
-
Neesha DhaniSeen in:
- Ontario, Toronto, University Health Network-Princess Margaret Hospital
Trials:- NCT03914612 (Principal Investigator)
Conditions:- Endometrial Clear Cell Adenocarcinoma;
- Endometrial Dedifferentiated Carcinoma;
- Endometrial Endometrioid Adenocarcinoma;
- Endometrial Mixed Cell Adenocarcinoma;
- Endometrial Serous Adenocarcinoma;
- Endometrial Undifferentiated Carcinoma;
- Recurrent Endometrial Adenocarcinoma;
- Recurrent Endometrial Carcinoma;
- Recurrent Endometrial Clear Cell Adenocarcinoma;
- Recurrent Endometrial Dedifferentiated Carcinoma;
- Recurrent Endometrial Endometrioid Adenocarcinoma;
- Recurrent Endometrial Mixed Cell Adenocarcinoma;
- Recurrent Endometrial Serous Adenocarcinoma;
- Recurrent Endometrial Undifferentiated Carcinoma;
- Stage III Uterine Corpus Cancer AJCC v8;
- Stage IV Uterine Corpus Cancer AJCC v8
-
Nidhi Kumar TyagiSeen in:
- Ontario, Hamilton, Juravinski Cancer Centre at Hamilton Health Sciences
Trials:- NCT03914612 (Principal Investigator)
Conditions:- Endometrial Clear Cell Adenocarcinoma;
- Endometrial Dedifferentiated Carcinoma;
- Endometrial Endometrioid Adenocarcinoma;
- Endometrial Mixed Cell Adenocarcinoma;
- Endometrial Serous Adenocarcinoma;
- Endometrial Undifferentiated Carcinoma;
- Recurrent Endometrial Adenocarcinoma;
- Recurrent Endometrial Carcinoma;
- Recurrent Endometrial Clear Cell Adenocarcinoma;
- Recurrent Endometrial Dedifferentiated Carcinoma;
- Recurrent Endometrial Endometrioid Adenocarcinoma;
- Recurrent Endometrial Mixed Cell Adenocarcinoma;
- Recurrent Endometrial Serous Adenocarcinoma;
- Recurrent Endometrial Undifferentiated Carcinoma;
- Stage III Uterine Corpus Cancer AJCC v8;
- Stage IV Uterine Corpus Cancer AJCC v8
-
Stephen A. WelchSeen in:
- Ontario, London, London Regional Cancer Program
Trials:- NCT03914612 (Principal Investigator)
Conditions:- Endometrial Clear Cell Adenocarcinoma;
- Endometrial Dedifferentiated Carcinoma;
- Endometrial Endometrioid Adenocarcinoma;
- Endometrial Mixed Cell Adenocarcinoma;
- Endometrial Serous Adenocarcinoma;
- Endometrial Undifferentiated Carcinoma;
- Recurrent Endometrial Adenocarcinoma;
- Recurrent Endometrial Carcinoma;
- Recurrent Endometrial Clear Cell Adenocarcinoma;
- Recurrent Endometrial Dedifferentiated Carcinoma;
- Recurrent Endometrial Endometrioid Adenocarcinoma;
- Recurrent Endometrial Mixed Cell Adenocarcinoma;
- Recurrent Endometrial Serous Adenocarcinoma;
- Recurrent Endometrial Undifferentiated Carcinoma;
- Stage III Uterine Corpus Cancer AJCC v8;
- Stage IV Uterine Corpus Cancer AJCC v8
Clinical Trials on Carcinoma, Endometrioid
-
National Cancer Institute (NCI)NRG OncologyCompletedFIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma | FIGO Grade 3 Endometrial Endometrioid AdenocarcinomaUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingEndometrial Endometrioid AdenocarcinomaUnited States
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Malignant Ovarian Endometrioid Tumor | Ovarian High Grade Serous Adenocarcinoma | Platinum-Sensitive Ovarian Carcinoma | Fallopian Tube High Grade Serous Adenocarcinoma and other conditionsUnited States
-
Women and Infants Hospital of Rhode IslandUnknownGrade 1 Endometrial Endometrioid Adenocarcinoma | Grade 2 Endometrial Endometrioid Adenocarcinoma | Complex Atypical Endometrial HyperplasiaUnited States
-
Fudan UniversityWithdrawnEndometrial Endometrioid AdenocarcinomaChina
-
NRG OncologyNational Cancer Institute (NCI)CompletedEndometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Uterine Corpus Cancer | Metastatic Endometrioid AdenocarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingFallopian Tube Carcinoma | Ovarian Carcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Primary Peritoneal Carcinoma | Ovarian High Grade Serous Adenocarcinoma | Primary Peritoneal Endometrioid Adenocarcinoma | Ovarian...United States
-
HonorHealth Research InstituteMerck Sharp & Dohme LLC; Salarius Pharmaceuticals, LLCWithdrawnOvarian Endometrioid Adenocarcinoma | Endometrial Cancer | SCCOHT | Ovarian Clear Cell TumorUnited States
-
National Cancer Institute (NCI)NRG OncologyRecruitingOvarian Endometrioid Adenocarcinoma | Endometrial Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Platinum-Resistant Ovarian Carcinoma | Endometrial Low Grade Endometrioid... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingEndometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia | FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma | Atypical HyperplasiaUnited States